1. Home
  2. OPT vs DDL Comparison

OPT vs DDL Comparison

Compare OPT & DDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPT
  • DDL
  • Stock Information
  • Founded
  • OPT 1984
  • DDL 2014
  • Country
  • OPT Australia
  • DDL China
  • Employees
  • OPT N/A
  • DDL N/A
  • Industry
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • DDL Catalog/Specialty Distribution
  • Sector
  • OPT Health Care
  • DDL Consumer Discretionary
  • Exchange
  • OPT Nasdaq
  • DDL Nasdaq
  • Market Cap
  • OPT 855.6M
  • DDL 731.2M
  • IPO Year
  • OPT 2020
  • DDL 2021
  • Fundamental
  • Price
  • OPT $5.09
  • DDL $3.70
  • Analyst Decision
  • OPT Strong Buy
  • DDL Sell
  • Analyst Count
  • OPT 1
  • DDL 1
  • Target Price
  • OPT $12.00
  • DDL $1.15
  • AVG Volume (30 Days)
  • OPT 40.1K
  • DDL 507.8K
  • Earning Date
  • OPT 03-03-2025
  • DDL 03-03-2025
  • Dividend Yield
  • OPT N/A
  • DDL N/A
  • EPS Growth
  • OPT N/A
  • DDL N/A
  • EPS
  • OPT N/A
  • DDL 0.13
  • Revenue
  • OPT $261,859.00
  • DDL $3,158,412,712.00
  • Revenue This Year
  • OPT N/A
  • DDL $17.81
  • Revenue Next Year
  • OPT $46,864.26
  • DDL $16.81
  • P/E Ratio
  • OPT N/A
  • DDL $28.42
  • Revenue Growth
  • OPT N/A
  • DDL 4.61
  • 52 Week Low
  • OPT $1.79
  • DDL $1.08
  • 52 Week High
  • OPT $6.30
  • DDL $4.79
  • Technical
  • Relative Strength Index (RSI)
  • OPT 53.99
  • DDL 62.25
  • Support Level
  • OPT $4.77
  • DDL $3.30
  • Resistance Level
  • OPT $5.46
  • DDL $3.60
  • Average True Range (ATR)
  • OPT 0.32
  • DDL 0.16
  • MACD
  • OPT -0.11
  • DDL 0.05
  • Stochastic Oscillator
  • OPT 20.60
  • DDL 77.27

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

About DDL Dingdong (Cayman) Limited (each two representing three)

Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.

Share on Social Networks: